Recent News and Upcoming Events

First Light Diagnostics Receives FDA Clearance for its Rapid Clostridiodes difficile Test on the MultiPath® Analyzer

First FDA cleared product based on the Company’s proprietary MultiPath technology Chelmsford, MA (Jul 20, 2021) – First Light Diagnostics is developing and commercializing breakthrough automated diagnostic products for rapidly detecting infections and determining optimal treatment. The company announced today that the US Food and Drug Administration (FDA) has cleared its SensiTox™ C. difficile Toxin…

Read More

First Light Diagnostics Appoints Joanne Spadoro as Chief Executive Officer

Chelmsford, MA (May 5, 2021) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic resistant infections, has named Joanne Spadoro, PhD as President and Chief Executive Officer (CEO). As the CEO of First Light Diagnostics, Dr. Spadoro will be responsible for leading the company through the…

Read More

First Light Diagnostics Receives Additional Funding from the Biomedical Advanced Research and Development Authority (BARDA)

Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test Chelmsford, MA, October 27, 2020 – First Light Diagnostics, Inc., a developer of breakthrough automated products for the rapid diagnosis and treatment of life-threatening infections, today announced the authorization of a $4 million award from the Biomedical Advanced Research and Development Authority (BARDA), part…

Read More

First Light Diagnostics Names New Chief Financial Officer

Life Sciences Veteran Andrew Wilsack Joins Team Chelmsford, MA (May 28, 2020) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, has appointed Andrew Wilsack as the company’s new CFO. “Andrew’s broad experience across disciplines will be an asset for us,” said David Macdonald,…

Read More

First Light Diagnostics Posters and Abstracts Accepted, Part of ECCMID 2020 Abstract Book

Chelmsford, MA (May 21, 2020) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the acceptance of two posters as part of the 30th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). With global resources focused on combatting the current…

Read More

What Sets Us Apart?

Our MultiPath benchtop analyzer is advancing the field of rapid diagnostics in several key areas:

Culture Free Results

Culture Free Results

The MultiPath technology outperforms current culture-based methods by providing pathogen identification results in 30 minutes and antimicrobial susceptibility test results in 4 hours…without a sample culture step.
Hours vs. Days

Hours vs. Days

Culture-free test capabilities make MultiPath the ONLY platform capable of delivering diagnostic results in hours as compared to multiple days required for current, culture-based tests.
Therapy at the Onset of Infection

Therapy at the Onset of Infection

Rapid Diagnostic ID/AST results provide timely, actionable data for clinicians to make the best therapy decisions for their patients at the onset of infection.

How First Light Diagnostics Can Help Patients Receive the Right Therapy at the Onset of Infection

Meet the Team

Management Team
Board of Directors
Clinical Advisory
Other Advisors
light-purple-logo

Contact First Light Diagnostics

If you have been watching the continued growth and development of this exciting company and would like to speak with us, please fill out the form below and we will work with you to coordinate a one on one meeting.



Role in your Organization*







Recent Publications/Posters

(Peer Reviewed Article) A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples
A New Method for Rapid Phenotypic AST Directly from Patient Samples

Recent Industry articles on the Antibiotic Resistance Problem

Menu